title: Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis.
abstract: OBJECTIVE
  It has been reported that a single dose of human C-reactive protein (CRP) can prevent and reverse the renal damage in murine models of spontaneous lupus, as well as the rapid-onset immune complex disease induced in the accelerated nephrotoxic nephritis (ANTN) model. This study was undertaken to attempt to replicate these observations using a highly purified and fully characterized human CRP preparation.
  
  
  METHODS
  (NZB x NZW)F(1) (NZB/NZW) mice were treated with a single 200-microg subcutaneous injection of CRP or control reagents either before disease onset at 4 months of age or when high-grade proteinuria was present at 7 months of age. Mice were monitored at least monthly for proteinuria and autoantibody levels. ANTN was induced by preimmunizing C57BL/6 mice with sheep IgG, followed 5 days later by injection of sheep anti-mouse glomerular basement membrane antibody and CRP or control reagents. Renal disease was assessed by regular urinalysis and histologic evaluation.
  
  
  RESULTS
  CRP treatment of NZB/NZW mice, either early or late in the disease, had no effect on proteinuria, autoantibody titers, or survival. CRP administration did not reduce renal injury or alter disease in the ANTN model. Human serum amyloid P component, a pentraxin protein that is very closely related to CRP, similarly had no effect.
  
  
  CONCLUSIONS
  Our completely negative observations do not confirm that human CRP has reproducible antiinflammatory or immunomodulatory effects in these murine models, nor do they support the suggestion that CRP might be useful for therapy of lupus or immune complex-mediated nephritis.
authors.affiliation: Imperial College London, London, UK.
authors.forename: Francesco
authors.initials: F
authors.lastname: Carlucci
authors.forename: H Terence
authors.initials: HT
authors.lastname: Cook
authors.forename: Abhilok
authors.initials: A
authors.lastname: Garg
authors.forename: Mark B
authors.initials: MB
authors.lastname: Pepys
authors.forename: Marina
authors.initials: M
authors.lastname: Botto
mesh_terms: D000818:Animals; D002097:C-Reactive Protein / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology; D008136:Longevity / Q000187:drug effects; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008814:Mice, Inbred NZB; D009393:Nephritis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D002097:C-Reactive Protein